Sign up to save your podcasts
Or
Share Episode 5: Brexit Pharma - No Rating Changes, But Negative Implications
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 5: Brexit Pharma - No Rating Changes, But Negative Implications
Healthcare analysts Arthur Wong and Adam Dibe discuss their quick thoughts on Brexit and what it means for U.S. rated pharma companies. No rating changes at this time, but some concerns on what Brexit may mean for product approval times and research funding.
View all episodes
By SP Global RatingsHealthcare analysts Arthur Wong and Adam Dibe discuss their quick thoughts on Brexit and what it means for U.S. rated pharma companies. No rating changes at this time, but some concerns on what Brexit may mean for product approval times and research funding.